BIT Biotron Limited
Healthcare · Biotechnology
· website
$0.00
52wk 0.00 – 0.01
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$5.57M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
-0.64
EV / EBITDA
-1.61
Price / Book
2.00
ROE
-122.6%
Operating margin
226,598.1%
Net margin
0.0%
Total cash
$1.64M
Total debt
$0
Current ratio
1.47
Debt / Equity
—
Free cash flow
$-587,568
Avg volume
1.03M
Latest annual results
(FY ending 30 Jun 2024)
- Revenue—
- Gross profit—
- Operating income-$5.15M
- Net income-$3.44M
- Diluted EPS-0.00
- Free cash flow-$3.57M
- Net debt-$386.07K